Kardigan Status update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning. We are going to get started bright and early. Appreciate everybody coming today. We are going to talk a little bit about aortic stenosis. Thanks for meeting us here in Chicago. For those of you who do not know me, my name is Tassos Giannakakos. I am CEO of Kardigan, and I am really glad to be here with you today and with leading cardiologists to talk about Kardigan's mission in aortic stenosis. Before we begin, let me give you guys the most exciting news of the day here. I would like to remind you that certain statements made during the call may include forward-looking statements, including those relating, but not limited to, the therapeutic potential and safety of ataciguat, and our expectations regarding the design, endpoints, timing, and outcome of our current and future clinical trials, including KATALYST-AV.
Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in our most recent quarterly report on Form 10-Q filed with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements, and Kardigan disclaims any obligation to update such statements unless required by law. That is the short version. All right. We will start with the news on KATALYST-AV, our phase II study of ataciguat in aortic stenosis. It is fully enrolled, so this is big news for us. It is a foundational milestone for the program at Kardigan, but it is also a really important one for people living with aortic stenosis.
Today, we are going to share what we have learned along the way from one of the largest real-world data sets that has been ever analyzed in aortic stenosis and from our KATALYST-AV baseline data as well. Those insights have told us much more clearly which patients progress fast, and they directly shape how we are going to plan our development program and our registrational phase III trials. Today, you are going to hear from members of our team who are in the audience, some that you see here up on the screen as well, and from thought leaders in aortic stenosis.
First up after me will be Dr. Sreekanth Vemulapalli of Duke on real-world progression, and then you will hear from Professor Philippe Pibarot of the Quebec Heart and Lung Institute on how we measure the valve and the heart, and he will share his thoughts as well on the KATALYST-AV baseline data. Finally, you are going to hear from our Cheryl Abrams. She is our global program head for ataciguat. She will share specific impact of all of this on our KATALYST-AV program. We will have some time at the end to open it up for questions, so hopefully you guys will have a few for us, and we will be ready to take them. All right, so four things to start first that have really shaped how we are developing ataciguat. First, there is no approved medicine for aortic stenosis. Patients wait till the valve is bad enough to replace.
A therapy that slows progression would really change that and revolutionize the space. Second, patients don't all progress at the same pace. A subset moves much faster, and they're the ones who end up needing valve replacement and end up in the hospital with heart failure. Third, this is one disease with two linked pathways, the valve and the heart muscle. Damage to the heart can begin well before the valve is severe. Fourth, ataciguat has the potential to act on both of these pathways, on the valve and directly on the heart muscle. Here's why this matters. With enrollment now complete, our baseline data and the real-world analyses, they're done, and they point to potential markers of rapid progression. This is what we set out to learn. This is intentional. It's what you really hope for in a clinical program, particularly one that affects so many people.
Now that we have that, we set out to learn about this on day one of the program, and it's really going to be very helpful. Based on the analysis that we're going to share, we're now able to sharpen how we select patients for phase III, what the right endpoints are to measure, and how long we need to treat to see a meaningful benefit. Cheryl is going to get into many more of these details and what it means for KATALYST-AV in just a little bit. Let's look a little bit at what we knew coming into today's analysis. We're looking here at a meta-analysis of published data, and they point to an important finding.
A meaningful subset of patients with aortic stenosis progress rapidly, and these patients have worse outcomes. On average, valve area declines by about 0.08 square centimeters a year. Fast progressors can lose more than twice that. If you look at the chart, if you're starting from a moderate disease state, a fast progressor can reach a severe aortic stenosis in under three years, while a typical patient is still moderate at five. In moderate AS, about 30% of patients are fast progressors. It is not a small segment, and they have more than three times the rate of valve replacement and a higher risk of death. These findings, by the way, have been independently corroborated around the same time here, a couple weeks ago from the PROGRESSA study as well. We could get into that a little bit later.
The question for us looking at this data was simple. How do these patients progress? What drives their worst outcome, their worsening outcomes? What defines a fast progressor, and importantly, can we identify them in advance? That's what we set out to understand and inform our ataciguat program, and I'm really happy that we've been able to do that. To answer those specific questions and start getting us into the nitty-gritty, we went to one of the largest real-world data sets to assess aortic stenosis. There's more than 45,000 patients in that data set. Here to walk us through it is Dr. Sreekanth Vemulapalli. He's Associate Professor of Medicine and Medical Director of the Echo Lab at Duke. Sreek, I'm going to hand it over to you.
All right. Thank you, Tassos. I want to walk you through what we did here. Again, to reinforce something that Tassos said, we really have two different pathways and mechanisms going on here. We have the valve, of course, and even within the valve, there are a couple different things happening here. We often think about the fibrocalcific process that is going on. I will say that again, fibrocalcific process, not just calcification. We also have aortic valve area, and these two things are somewhat related, but not exactly the same thing. Patients often go through a progression of going from sclerosis to mild AS to moderate AS to severe AS, but in the real world, they often sort of jump between mild to severe because they do not get checked in between. Independently of that, but again, somewhat related, is cardiac function or dysfunction.
There are other changes going on besides the valve that include the ventricle. We have LV mass index, so the mass of the ventricle gets larger. We get diastolic dysfunction. This means when the ventricle is relaxing, it is not relaxing appropriately. Then we get enlargement of various portions of the heart, including the left atrium. Finally, we get a reduction in the actual output of the myocardium. It is important to keep these two pathways in mind. They are distinct but related, and these things result in heart failure events, aortic valve replacement, and death. What we did was we looked at multiple health systems, and we tried to define a population of patients with mild and moderate aortic stenosis. We started with about 160,000 patients with aortic stenosis, as identified by natural language processing and ICD-10 codes.
We got down to an analysis population of about 45,000 patients with mild and moderate disease and discordant disease. Then of those, 20,000 patients actually had enough information with multiple echocardiograms within a two-year period to look at annual progression. We defined fast progression based on accepted values within the literature, so aortic valve area change of 0.1 centimeters squared per year or more, or a peak jet velocity gain of 0.3 meters per second per year or more. What did we find here? The key takeaway from this point is almost one in four patients with mild to moderate AS are fast progressors. You can see there, 27%. In fact, it is not just that we saw one in four are fast progressors, but in fact, the progression that they had is faster than what we saw in the previously published literature.
You can see what we found was a change of about 0.12 centimeters squared per year, as opposed to what is in the literature of 0.08. In fact, our normal progressors averaged around 0.08 in this analysis. What does that actually mean? Okay, we defined about one in four are fast progressors. Well, it is as you would expect. These fast progressors have worse outcomes. Valve replacement or repair, 3.1 times risk for that for fast progression. Acute all-cause hospitalization, 1.5 times risk. Worsening heart failure, so this is heart failure hospitalization plus heart failure events, outpatient events that required an intervention in terms of medication, that is 1.3 times. All-cause death, 1.2 times. These are substantial event rates. Take a look at the all-cause hospitalization. That is 35 out of 100 patient years, so substantial rates. Okay. In parallel to looking at fast progression of the valve as defined by AVA or peak velocity, we were looking at the myocardium.
This is really important. There's a growing literature to suggest that amongst patients, at least with severe AS, that myocardial damage is directly associated with outcomes. It's less well-known whether that's true in mild or moderate AS, and we're going to show you that data. Just to remind you again, we're looking at LV mass index, we're looking at left atrial volume index, we're looking at stroke volume index as well, and then measures of diastolic function such as E prime or E over E prime. So what did we find?
About four in five patients, just about 80% of patients in this cohort of mild or moderate AS, actually have cardiac dysfunction as we defined it, and that's very much in line with what's in the literature, which is between 75% and 80%. The next key point is that fast progression is more prevalent in patients with cardiac damage. Take a look at the graph on the right. 28% have cardiac damage versus 19% without cardiac damage, so more prevalent there. What does that mean? Patients with cardiac damage have worse outcomes. Here, look at the red dots here in the forest plot. Valve replacement or repair more likely with cardiac damage, all-cause hospitalization, worsening heart failure, all-cause death, and heart failure hospitalization all worse with cardiac damage.
Some of you may be thinking at this point, you've spent some time talking about AVA, you've spent some time talking about the myocardium, but we've all been told that aortic valve calcification is the thing. Why aren't you talking about that? I think this data is really important. Two points here. Number one, between fast progressors and normal progressors, the aortic valve calcification values in this cohort were not substantially different, okay? We already just showed you that fast progression is a marker of bad outcomes. But here, aortic valve calcification, not different. Also, look at the actual values. Here's a distribution in this plot, but the red values are the fast progressors, and the gray values are the normal progressors. Notice the aortic valve calcifications are at least numerically lower in the fast progressors than in the normal progressors.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
